Ekso Bionics(EKSO)

Focus: Ekso Bionics designs and commercializes exoskeleton robotics for rehabilitation of spinal cord injuries and mobility impairments. The company is a publicly traded medical device innovator with $18M in annual revenue, operating at modest scale.

Profile data last refreshed 15h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Ekso Bionics

AI assessmentNot Hiring

No open roles listed right now. Follow Ekso Bionics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$18M

Key Products

Ekso GT Rehabilitation Therapy

Spinal Cord Injuries

Growth

Primary commercial exoskeleton product for rehabilitation therapy in spinal cord injury patients.

EksoGT with SmartAssist software

Debility Due to Disease

Help build intelligence for Ekso Bionics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering medical robotics technology in a high-growth market segment with limited competition
Public company status provides equity upside potential and established corporate infrastructure
R&D-focused operation (22% of revenue) creates roles for engineers, roboticists, and biomedical scientists

Watch Out For

Severe cash burn: company lost $11.3M on $18M revenue in FY2025, with only $4M cash on hand, raising near-term funding risk
Zero current job openings and no reported headcount suggests organizational contraction or hiring freeze

Generated by Claude from Ekso Bionics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Enhanced software version expanding indication scope beyond spinal cord injuries to broader debility conditions.

Pipeline & Clinical Trials

Ekso GT Rehabilitation Therapy

Injuries, Spinal Cord

N/A

Clinical Trials (1)

NCT02943915The WISE Trial - Walking Improvement for SCI With Exoskeleton

N/A

Ekso

Spinal Cord Injury

N/A

Clinical Trials (1)

NCT02132702Performance Attributes and User Progression While Using Ekso

N/A

EksoGT with SmartAssist software

Debility Due to Disease

N/A

Clinical Trials (1)

NCT03355755Exoskeleton Treatment of Deconditioning Due to Limited Ambulation Caused by Illness or Injury

N/A

Ekso

Spinal Cord Injuries

N/A

Clinical Trials (1)

NCT02566850Investigational Study of the Ekso for High-Dosage Use by Individuals With SCI in a Non-Clinical Environment

N/A

Overground Robotic Exoskeleton

Spinal Cord Injury

N/A

Clinical Trials (1)

NCT07030322Health and Financial Impact on the Use of a Personal Exoskeleton in the Home and Community: a Case Study

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2005

Portfolio: 5 clinical trials

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Financials (FY2025)

Revenue

$18M2%

R&D Spend

$4M(22%)23%

Net Income

-$11M

Cash

$4M

Source: SEC 10-K Filing

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles